Your browser doesn't support javascript.
loading
Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany.
Griesinger, Frank; Pérol, Maurice; Girard, Nicolas; Durand-Zaleski, Isabelle; Zacharias, Stefan; Bosquet, Lise; Jänicke, Martina; Quantin, Xavier; Groth, Annika; Fleitz, Annette; Calleja, Alan; Patel, Sonya; Lacoin, Laure; Daumont, Melinda J; Penrod, John R; Carroll, Robert; Waldenberger, Daniela; Reynaud, Dorothée; Thomas, Michael; Chouaid, Christos.
Affiliation
  • Griesinger F; Department of Haematology & Oncology, University Department Internal Medicine-Oncology, Pius-Hospital, University Medicine Oldenburg, Oldenburg, Germany. Electronic address: Frank.Griesinger@Pius-Hospital.de.
  • Pérol M; Department of Medical Oncology, Léon Bérard Cancer Centre, Lyon, France.
  • Girard N; Curie Institute, Paris, France; UVSQ, Paris Saclay University, Versailles, France.
  • Durand-Zaleski I; Université Paris Est Créteil, AP-HP Health Economics Research Unit, Hotel Dieu Hospital, INSERM UMR 1153 CRESS, Clinical Epidemiology (Methods) Research Team, Paris, France.
  • Zacharias S; Department of Biostatistics, iOMEDICO, Freiburg, Germany.
  • Bosquet L; Health Data and Partnerships Department, Unicancer Paris, France.
  • Jänicke M; Department of Epidemiology, iOMEDICO, Freiburg, Germany.
  • Quantin X; Montpellier Cancer Institute (ICM) and Montpellier Cancer Research Institute (IRCM), INSERM U1194, University of Montpellier, Montpellier, France.
  • Groth A; AIO-Studien-gGmbH, Berlin, Germany.
  • Fleitz A; Department of Epidemiology, iOMEDICO, Freiburg, Germany.
  • Calleja A; Real World Solutions, IQVIA, London, UK.
  • Patel S; Real World Solutions, IQVIA, London, UK.
  • Lacoin L; Epi-Fit, Bordeaux, France.
  • Daumont MJ; Worldwide Health Economics & Outcomes Research, Bristol Myers Squibb, Braine-L'Alleud, Belgium.
  • Penrod JR; Worldwide Health Economics & Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA.
  • Carroll R; Centre for Observational Research & Data Sciences, Bristol Myers Squibb, Uxbridge, UK.
  • Waldenberger D; Medical Oncology, Bristol Myers Squibb GmbH & Co. KGaA, Munich, Germany.
  • Reynaud D; Medical Oncology, Bristol Myers Squibb, France.
  • Thomas M; Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Germany.
  • Chouaid C; Pneumology Unit, Centre Hospitalier Intercommunal de Créteil, Créteil, France.
Lung Cancer ; 172: 65-74, 2022 10.
Article in En | MEDLINE | ID: mdl-36007281
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Lung Cancer Journal subject: NEOPLASIAS Year: 2022 Document type: Article Country of publication: Ireland
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Lung Cancer Journal subject: NEOPLASIAS Year: 2022 Document type: Article Country of publication: Ireland